Sections in This Document

1. Purpose .................................................................................................................................... 2
2. Scope ....................................................................................................................................... 3
3. Responsibility ............................................................................................................................ 3
4. Background ............................................................................................................................... 3
5. References ............................................................................................................................... 5
6. Procedure ................................................................................................................................... 8
   6.1. Methodology ................................................................................................................... 8
       6.1.1. Introduction ...................................................................................................... 8
       6.1.2. Methodology Sources ...................................................................................... 8
       6.1.3. Questions ....................................................................................................... 11
6.2. Pharmaceutical Chemistry ........................................................................................... 11
       6.2.1. Pharmaceutical Products Overview ............................................................... 11
       6.2.2. Questions ....................................................................................................... 13
6.3. Instrumentation and Technique ..................................................................................... 14
       6.3.1. Basic Analytical Techniques .......................................................................... 14
       6.3.2. Spectrophotometric Techniques .................................................................... 16
       6.3.3. Optical Rotation/Polarimeter (USP <781>) .................................................... 19
       6.3.4. Chromatographic Techniques ....................................................................... 20
       6.3.5. Other Specialized Techniques ....................................................................... 27
       6.3.6. Advanced Techniques ................................................................................... 29
6.4. Inspections/Investigations ............................................................................................ 30
7. Glossary/Definitions ................................................................................................................ 31
8. Records .................................................................................................................................. 31
9. Supporting Documents .......................................................................................................... 31
10. Document History .................................................................................................................. 32
11. Change History ....................................................................................................................... 32
12. Attachments ............................................................................................................................ 35
    Attachment A - Exercise – Practice with Samples ......................................................... 36
    Attachment B: Example – Proficiency Samples .............................................................. 41
    Attachment C: Statistical Analysis ................................................................................. 43
    Attachment D: Answer Key .............................................................................................. 46
    Attachment E. Column Chromatography Chart ............................................................ 69

For the most current and official copy, check QMiS.
1. Purpose

The drug analysis training program provides preliminary training in basic technical areas. The Office of Training, Education and Development (OTED) offers New Hire Laboratory Analyst Training curriculum (Bingo card) which specifies sections of the ORA Lab Manual as part of the New Hire Curriculum. Described are drug analyses for new hire training and suggested on-the-job training samples of selected techniques. Additional techniques and training exercises are included that are occasionally used in drug analysis.

The Center for Drugs and Evaluation Research (CDER) is responsible for establishing the inspectional and analytical guidelines associated with the FDA drug analysis programs. Drug Compliance Programs are found in the Compliance Program Guidance Manual (CPG).

This training chapter introduces the trainee to regulatory pharmaceutical analyses in FDA, analytical separation techniques, instrumentation, and the resolution to typical problems a trainee will encounter with pharmaceutical analyses. The trainee should discuss each exercise in advance with the trainer. If a laboratory does not perform analyses in that area, that portion of the training can be abbreviated or eliminated.

The training is separated into modules using defined pharmaceuticals. Before beginning the sample analysis, the trainer should consider and discuss topics that will cultivate a thoughtful and responsible approach to each assignment. Topics may include the following:

A. Why was the sample collected? (assume it was not a training sample). Does the sample match the description on the collection report?

B. Criteria for method selection. What care is taken in selecting an analytical method? Is the method the correct one? Is the method valid?

C. Correct sample handling. Is there a microbiological analysis associated with this sample that may necessitate the microbiologists to handle the sample first?

D. Is there enough sample for all the regulatory tests? For an additional and check analysis? For an exhibit, if needed?

E. Does the sample have an expiration date that would impact the validity of test results?

F. What regulatory action might result from the analysis of the sample?

For the most current and official copy, check QMiS.
When the trainee has completed each exercise, the analysis, worksheet preparation, and answers to the questions should be discussed thoroughly. The analyst also shows that they are proficient in the technique and instrumentation.

2. Scope

The incumbent is a regulatory scientist in an FDA/ORA field laboratory and is expected to bring full professional competence in his/her discipline to bear in carrying out analyses and interpreting the significance of test results. The incumbent is assigned scientific analyses on a wide range of samples including those that are difficult, complex, or unusual.

These responsibilities support the FDA and its mission to support public health through the regulation of products and manufacturers under the jurisdiction of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and Related Acts.

3. Responsibility

A. Trainer
   1. Coordinates training with Supervisor(s) and Trainee.
   2. Works with trainees to ensure completion of all training needed to meet their regulatory responsibilities.

B. Trainee
   1. Completes required training within specified timeframes.
   2. Reports training received and submits documentation for training to supervisor.

C. Supervisor
   1. Implements and reviews training records.

D. Quality Management
   1. Maintains employee competencies matrix records for staff.

4. Background

The Food and Drug Act of June 30, 1906 prohibited adulteration and misbranding of drugs in interstate commerce. Following an adverse ruling (United States v. Johnson) by the Supreme Court of the United States in 1911,
Congress passed the Sherley Amendment the same year, which added to the Act a prohibition against claims of curative or therapeutic effects being placed on the package label with intent to defraud the purchaser. The burden of proof of adequacy of claims, however, was on the government. Prior testing of drugs for safety was not addressed.

In early 1938, the Wheeler-Lea Amendment to the Federal Trade Commission (FTC) Act clarified the jurisdiction of advertising between the FTC and the FDA. The FTC reserved control of drug advertising. The weakening of FDA authority, in conjunction with the “Elixir of Sulfanilamide” drug-related disaster, paved the way for the passage of a completely new law.

The "Elixir of Sulfanilamide" tragedy of 1937 killed 107 people due to the use of the solvent diethylene glycol in the product. Since the law did not require prior testing of drugs for safety, there was no way to anticipate, or prevent, the marketing of this lethal mixture.

The Federal Food, Drug, and Cosmetic Act (FD&C Act) was passed on June 25, 1938. The new law prohibited the marketing of "new drugs," (a term defined in the FD&C Act), unless the new drug had been tested and found to be safe for use under the prescribed conditions. The new law also required the active drug ingredient names and amounts be declared and defined labeling be found on habit forming drugs. For false or fraudulent drug claims, the requirement that intent be demonstrated was dropped.

The Durham-Humphrey Amendment of 1951 defined the term "prescription drug"; these drugs could only be dispensed with a legal prescription. Over-the-counter (OTC) drugs were to bear labeling that contained directions for use, and warnings against misuse.

In 1962, the Thalidomide drug disaster, which demonstrated the danger of incomplete drug testing prior to clinical trials, ensured the passage of sweeping drug control legislation. Thalidomide, a sedative taken during pregnancy, was found to cause the deformity known as phocomelia in children. The drug had never been approved for commercial sale in the United States. The use of this drug during pregnancy caused nine children in the United States to be born with this deformity. The tragedy had much greater proportions in Europe where thalidomide had been widely distributed.

Congress passed the Kefauver-Harris Drug Amendments on October 10, 1962, which answered the need for tighter controls over drugs. These amendments included the following changes:

A. FDA was authorized to establish current good manufacturing practices (cGMPs) for drugs.

B. Drug manufacturers were required to register annually.
C. A drug is proven to be safe and effective by the manufacturer. A new drug could no longer be marketed prior to FDA approval based on convincing evidence of the drug's safety and effectiveness.

D. Reasons were listed for which a previously approved drug could be removed from the market.

E. New controls were placed on experimental and investigational drugs.

F. Regulation of advertising of prescription drugs was returned to FDA.

The Drug Listing Act of 1972 amended the FD&C Act so that drug establishments that are engaged in the manufacturing, preparation, propagation, compounding, or processing of a drug are required to register their establishments and list all their commercially marketed drug products with the FDA. Giving the agency means to readily determine which drugs were being manufactured and commercially distributed.

In 2012, an outbreak of fungal meningitis linked to a contaminated compounded drug product resulted in the loss of 64 lives and caused more than 751 illnesses. In response, Congress enacted the 2013 Drug Quality and Security Act (DQSA) that insures greater regulatory oversight of facilities creating compounded drugs. Among other provisions it outlines steps for an electronic and interoperable system to identify and trace certain prescription drugs throughout the U. S.

5. References

A. "Requirements of Laws and Regulations Enforced by the U.S. Food and Drug Administration".

B. Chapter V of the FD&C Act.


D. Read the pertinent sections of "A Brief Legislative History of the Food, Drug, and Cosmetic Act".

E. Chapter 1 of Bane's "Principles of Regulatory Drug Analysis" (See Section 9K) and Part 1 of "A Chemist's Guide to Regulatory Drug Analysis" (See Section 9L).

F. Compliance Policy Guidance Manual, Chapter 4, Subsection 400, Human Drugs.

G. Official Methods of Analysis of AOAC International (current ed.)
H. International Federation of Pharmaceutical Manufacturers Associations is a channel to exchange information within the international industry and various international organizations. Find International Conference on Harmonization (ICH) guidelines and related issues.

I. CDER Medical Library website includes e-journals, FDC Reports, and WebLERN site that includes the USP current version with monographs, American Drug Index, Physician’s Drug Reference, Drug Facts and Comparisons, and other useful information.

J. Material Safety Data Sheets, Toxicology Reports, and other safety information.

K. A brief legislative history of the food, drug, and cosmetic History of FDA


O. U. S. Food and Drug Administration, Office of Regulatory Affairs, Office of Enforcement. Compliance policy guides.


R. United States Pharmacopeia and National Formulary (current ed.).


For the most current and official copy, check QMiS.
Drug Chemistry Analysis


KK. The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Merck & Co., Inc., Whitehouse Station, NJ. (most recent edition).

For the most current and official copy, check QMiS.
6. Procedure

6.1. Methodology

6.1.1. Introduction

Modern pharmaceutical analysis has evolved from partitioning an active ingredient into a volatile solvent and performing a titration or gravimetric analysis, to techniques that include almost every known analytical procedure. Spectrophotometry is performed in the three most accessible regions of the spectrum - the ultraviolet, visible, and infrared. Atomic absorption, fluorescence, flame emission, and mass spectrometry (GC/MS and LC/MS) are also used. Pharmaceutical analysis now relies heavily on chromatographic techniques, especially high performance or pressure liquid chromatography (HPLC), since these techniques provide rapid, accurate, qualitative, as well as quantitative analysis. These techniques are also used to detect degradants and contaminants.

This section serves not only to review the methods, but more importantly, to understand where methods can be obtained for analyzing assigned drug samples. The analyst always considers two questions before beginning an analysis. Is the method the correct one? Is the method valid? This assignment will set the groundwork for answers to these questions.

6.1.2. Methodology Sources

6.1.2.1. Official Compendia

An "official compendium" is one that is officially cited in the FD&C. The United States Pharmacopeia (USP) (now combined with the National Formulary (NF)) is the major official compendium. The Homeopathic Pharmacopoeia is seldom used and is relatively obsolete. ORA Lab Manual, Volume IV, Section 1.3 Analytical Methods provides additional information on official compendia.

The USP/NF, published annually, is cited in the Food Drug and Cosmetic Act, 201, (g)(1), 201(j), 501(b).

The USP/NF contains valuable information. Analysts should become familiar with the location of the following sections found in the Table of Contents: "General Notices", "Monographs", "General Chapters", "Reagents", "Tables", and the sections of the NF. The General Chapters contains general tests and assay information, scientific principles and theory, as well as drug regulations and laws.

The Monographs section, comprising a major part of the USP/NF, serves as a definition and as a standard for a given drug substance, drug product, or drug...
ingredient. It is recommended that the analyst read the ‘General Notices and Requirements’ and several monographs noting their organization and content.

6.1.2.2. Petition Methods (NDAs and ANDAs)

Each New Drug Application (NDA) (PAC 46.832) or Abbreviated New Drug Application (ANDA) (PAC 52.832) includes a method for analysis of the final dosage form and in many cases the Active Pharmaceutical Ingredient (API). This is the control method used by the manufacturer, and it has been shown to be usable for regulatory purposes after review by the FDA. Methods in manufacturer’s Applications and Petitions that have been approved have “official” status. These include New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), New Animal Drug Applications (NADA), Food Additive Petitions (FAP), and Pesticide Petitions (PP).

All the material in these NDA and ANDA submissions are confidential and subject to the protection required by the FD&C Act, sections 301(j) and 303(a) (5). The analyst may not cite NDA or ANDA methods in a publication or discuss them with persons outside FDA. The documents require secure storage; the analysts are to be careful in how they handle the documents. Further document security and confidentiality information can be found in the following: The Supervisory Staff Manual Guides, FDA F:2280.2, “Physical Security in Field Activities,” Part 8, “Document Security,” and 21 CFR Part 31.14 (See Section 9B), “Confidentiality of Data and Information in a New Drug Application (NDA) File.”

For more information about the Method Validation samples refer to Compliance Program CP7346.832 (most current version) and “Supplement to CP7346.832 Pre-approval Inspections/Investigations, 7/8/96.”

6.1.2.3. AOAC Official Methods

The AOAC INTERNATIONAL (AOAC) Official Methods of Analysis of the AOAC (see Section 9 I) is specified in the Code of Federal Regulations, 21 CFR Part 2.19. Supplements, containing a cumulative index between editions, are published annually.

Sections to review in the AOAC include the following: “Definitions of Terms and Explanatory Notes,” page xv, “Microchemical Methods,” Chapters 18–22, Drugs I-V, and “Vitamins and Other Nutrients” During the review, note the presentation style and content found in these segments.

6.1.2.4. Pharmacopeial Forum

The Pharmacopeial Forum is a periodical issued six times a year by the United States Pharmacopeial Convention. It contains proposed new methods,
6.1.2.5. Compliance Programs

Many Drug Compliance Programs, especially surveillance sample programs (PAC 56008) contain analytical directions, methods or modification of methods to analyze products. The analyst needs to review the compliance program prior to analysis.

6.1.2.6. Code of Federal Regulations

Title 21 of the Code of Federal Regulations (CFR) provides labeling requirements for many pharmaceutical products. The CFR requirements frequently include official methodology to analyze the products. An example is “ANTACID PRODUCTS FOR OVER-THE-COUNTER (OTC) HUMAN USE” found in 21 CFR 331.

6.1.2.7. Journals and Other Literature

When methods are not located in the conventional sources mentioned above, there are applicable procedures found in the literature.

The Laboratory Information Bulletin (LIB) is a popular source of unofficial methodology in FDA published by the Office of Regulatory Science. The LIBs are an excellent source for methods and resolution to problems the analyst may encounter with a method. Consult the latest LIB cumulative index to see if another FDA analyst has already solved the problem. If there is a related LIB method, it may be advantageous to discuss the problem with the author.

The Journal of Pharmaceutical Sciences (J. Pharm. Sci.) and the Journal of AOAC INTERNATIONAL (J. AOAC Int.) are useful references. An annual index is found in the last journal for the year.

International Pharmaceutical Abstracts, which contains abstracts from the two journals found above, is an excellent key to the entire pharmaceutical literature.

The Analytical Profiles of Drug Substances/Analytical Profiles of Drug Substances and Excipients, containing a series of monographs found in over thirty volumes, is another excellent reference. The first set of twenty volumes is edited by Klaus Florey of Squibb Institute; the remaining volumes are edited by Harry G. Brittain of Ohmeda Pharmaceutical Products Division, Inc., and published by Academic Press. A table of contents and cumulative index is included in each volume.;
Other useful materials for completing the exercises that follow are given in Section 9M-AA.

6.1.3. Questions

A. What are the five most significant items of information in the USP "General Notices"? Compare the "General Notices" with the introductory chapter in the Official Methods.

B. Using the current USP, find the Dissolution procedure for Ascorbic Acid Tablets and how does it differ from most other Dissolution procedures?

C. Where in the USP is the listing for column types used in HPLC and GLC? How are they designated?

D. Locate the USP Reference Standards in the USP. What information is included here? What important information is missing and where is it found?

E. Obtain an NDA method and review it as one might review a research paper. Is it complete, specific, and unambiguous? Does it meet the requirements of the Code of Federal Regulations?

F. What does the term “Official Compendium” mean? Name the three major types of “official” methods used by FDA.

If a non-official method is used and the sample is violative, the check analysis must be performed using an official method or a Center approved method.

6.2. Pharmaceutical Chemistry

The exercises that follow are presented as modules providing examples of the techniques needed to analyze a variety of pharmaceuticals in a variety of dosage forms according to the associated Program Assignment Code (PAC). All exercises and topic discussions should be documented, approved, and the records placed in the trainee’s training file.

6.2.1. Pharmaceutical Products Overview

The following outline serves as a guide in developing and customizing a drug training program by delineating pertinent knowledge areas and concepts with which a drug chemist needs to be familiar.

USP < > refers to the General Chapters – General Tests and Assays, General Requirements for Tests and Assays found in the back of the USP/NF.

A. Modern Pharmacology
B. How a New Drug is developed
C. Standards (USP <11>)

For the most current and official copy, check QMiS.
Drug Chemistry Analysis

1. Working
2. USP
3. NIST
4. Other Pharmacopeial Standards

D. Controlled Substance--DEA Schedule

Schedule I, II, III, IV, V (USP 23/NF18, (1995), <1076> 'Controlled Substances Act Regulations') or earlier editions of USP/NF. Note: Later editions of USP/NF do not contain this section, however, the information is available in 21 CFR Part 1308: Schedule of Controlled Substances

E. How Drugs Work - drugs and receptors

F. Overview of the Chemistry of Organic Pharmaceuticals
   1. Basic Drugs and their Salts
   2. Acidic Drugs and their Salts
   3. Neutral Drugs

G. Drug Formulations (USP <1151> Pharmaceutical Dosage Forms)
   1. Tablets (immediate and extended release)
   2. Capsules (soft and hard gelatin)
   3. Liquid Products (solutions, elixirs)
   4. Topical Products (creams, ointments, gels, lotions)
   5. Injections (single and multidose)
   6. Transdermal patches and implants
   7. Other products (inhalation, aerosols, suppositories as listed in USP)

H. Types of Pharmaceuticals
   1. Analgesics
   2. Antianxiety - sedative, hypnotic
   3. Antiemetic
   4. Local anesthetics
   5. Antibiotics
   6. Antiviral
   7. Other
I. Excipient Performance (USP <1059>)
   1. bulking materials and fillers
   2. lubricants
   3. colorants

J. Drug Programs and Sample Types in FDA
   1. Compliance Samples: PAC 56002.
   2. Surveillance Samples: PAC 56008A, L
   6. Shelf-Life Extension Program: PAC 88D__.___.
   7. Import Samples: PAC 56008H & J.
   8. Method Validation Samples other than NDA/ANDAs.
   9. Other Program Samples: PAC 56021, 56021A & B, 56022A,
      61003, 63001.

6.2.2. Questions

A. When would you use a USP standard and when would you use a working standard? What is needed for working standards that is not needed for USP standards and why?

B. What is the procedure in the laboratory for obtaining USP standards? NIST standards? Controlled drug standards?

C. Describe the differences between an immediate release tablet/capsule, an extended release tablet/capsule and a delayed release tablet. How would someone classify transdermal patches and implants?

D. What items would likely be found in compressed tablets and what are their purpose? In capsules? Name at least three items.

E. Describe where to find the PAC code for a product.
6.3. Instrumentation and Technique

6.3.1. Basic Analytical Techniques

6.3.1.1. Objective
To review and use very basic analytical techniques and equipment (based on availability) routinely used in the laboratory (listed below). The student is expected to read and become familiar with the following techniques as described in the USP. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Volumetric Glassware (care, usage and calibration) (USP <31> [volumetric apparatus] and <841> [Specific Gravity]),
B. Balances and Weights (general, analytical, micro analytical) (USP <41> and USP <1251>),
C. Thermometers (mercury, alcohol, thermocouple) (USP<1118>),
D. pH (calibration and use) (USP <791>),
E. Melting Range/Temperature (USP <741>),
F. Gravimetric (USP <281> [Residue on Ignition] and <271> [Readily Carbonizable Substances Test]),
G. Titrations (aqueous and non-aqueous, pH, potentiometric) (USP <541>),
H. Water Determination (loss on drying <731>and KF titration, USP <921>),
I. Identification - Organic Nitrogenous Bases (USP <181>),
J. Uniformity of Dosage Units (USP <905>),
K. Dissolution (USP <711>) Apparatus 1 and 2,
L. Drug Release (USP <724>),
M. Tablet Friability (USP <1216>), Tablet Breaking Force <1217>

6.3.1.2. Exercises
Note: These tests may be performed in conjunction with other sub-sections of this section and need not be performed in order.

A. For the following exercises use product #1. ‘Acetaminophen (API)’ identified in Attachment A.
   1. Melting Range/Temperature (USP <741>), part 1.2

For the most current and official copy, check QMiS.
2. Gravimetric (USP <281> [Residue on Ignition] and <271> [Readily Carbonizable Substances Test]), parts 1.4 and 1.8, 
3. Water Determination (Method I, USP <921>), part 1.3, 
4. Limit Test, part 1.5, 
5. Organic Impurities (USP <621> and <1086>), part 1.6

B. For the following exercises use product #2. 'Ascorbic Acid Tablets' identified in Attachment A.
   1. Titrations (aqueous) Assay part 2.1, 
   2. Dissolution Test, Procedure for a Pooled Sample <711> part 2.3, 
   3. Uniformity of Dosage (USP <905> [Weight Variation]), part 2.4, and 

C. For the following exercises use product #8. 'Dextrose' identified in Attachment A.
   1. Water Determination (Method III) USP <921>, part 8.5, 
   2. Acidity - Titration (aqueous – limit test), part 8.4, 
   3. Identification – precipitate, part 8.1, and 

D. For the following exercise use product #7 ‘Saccharin’ identified in Attachment A.
   1. Titrations (aqueous) – Assay part 7.10

6.3.1.3. Questions

A. What other standard techniques can be used for determining Melting Range and why are these used? What standards are used for calibration of the Apparatus?

B. Why are limit and qualitative tests added to USP monographs? Compare the limit tests of the Acetaminophen product with those found in the Dextrose (including those not run). Which tests use the same method?

C. Both the Acetaminophen product and Dextrose have a method for Water. What is the difference between the two methods? Can Acetaminophen method be used for Dextrose? Can the Dextrose method be used for Acetaminophen? Explain the answers.
6.3.2. Spectrophotometric Techniques

6.3.2.1. Ultraviolet-Visible Spectroscopy (USP <857>) and Ultraviolet-Visible Spectroscopy-Theory and Practice (USP <1857>)

6.3.2.1.1. Objective
To learn or review essentials of quantitative UV/VIS spectrophotometry and to operate spectrophotometers in the laboratory for drug analysis (topics outlined below). The student is expected to read and become familiar with the following techniques as described in the USP or other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Theory
1. Essentials of spectrophotometry
   a. Ultraviolet Range
   b. Visible Range
   c. Near Infrared Range
2. Linearity
3. Limitations
4. Effects of solvent, pH and concentration

B. Instrumentation
1. Components:
   a. Source - Tungsten-halogen, Deuterium
   b. Monochromator – Single path, dual monochromator
   c. Sample compartment. - cuvettes (silica, glass, plastic)
   d. Detector
      i. Photomultiplier
      ii. Diode & Diode Array
2. Calibration Procedures
3. Data Collection and Handling
   a. Data Collection Systems
   b. Evaluating Spectra and Data
   c. Qualitation
6.3.2.1.2. Exercises

A. Run holmium oxide filter and compare wavelengths obtained with listed values.

B. Run potassium dichromate solutions and compare to listed values.

C. Using several standard solutions from the drug exercise below, check the linearity of the instrument in a range of 0.1 AU to 2.0 AU.

D. For the following exercises use product 1, ‘Acetaminophen (API)’ identified in Attachment A.

E. Identification Test B, UV <197U>, part 1.1, and

F. Assay – UV, part 1.8

6.3.2.1.3. Questions

A. Define: absorbance, absorptivity, molar absorptivity.

B. What is the typical cell size, specimen concentration and absorbance range used in the analysis of a substance in the UV or visible range?

C. What do the expressions "similar preparation" and "similar solution" indicate (as used in tests and assays involving spectrophotometry in the USP)?

D. What do the expressions "concomitantly determine" and "concomitantly measured" indicate (as used in tests and assays involving spectrophotometry in the USP)?

E. Good practice demands that comparisons be made at the wavelength at which peak absorption occurs. What difference in nm for the wavelength specified in the USP monograph is considered acceptable?

6.3.2.2. Mid-Infrared Spectroscopy (USP <854>) and Mid-Infrared Spectroscopy-Theory and Practice (USP <1854>)

6.3.2.2.1. Objective

To review the theory, instrumentation and proper techniques for FTIR sample preparation and analysis in the drug laboratory (topics outlined below). The student is expected to read and become familiar with the following techniques as described in the USP, other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.
A. Theory
   1. IR radiation
   2. Bonds
   3. Vibrations
   4. Resultant peaks
B. Instrumentation
   1. Fourier Transform
C. Sampling Techniques
   1. KBr pellets
   2. Liquid cell
   3. Salt plates
   4. ATR
D. FTIR instrument operation - Software –Programs, Macros
   1. Calibration
   2. Collect data
   3. Overlay
   4. Library Search
   5. Quantitation
E. Inspectional Aspects
   1. Calibration
   2. Quality of Spectra
   3. Accuracy

### 6.3.2.2. Exercises

A. Scan the IR spectrum of a thin (1.5 mil) film of standard polystyrene film and compare the major peaks (see below) with the IUPAC standard polystyrene spectrum.
B. For the following exercises use product 1. ‘Acetaminophen (API)’ identified in Appendix 1.

1. Identification Test A, Infrared <197K>, part 1.1

C. Use the library function of the FTIR, if present, to compare spectra with that in the library database.

**6.3.2.2.3. Questions**

A. What is FTIR?

B. What is the advantage of an FTIR spectrometer (interferometer) over a conventional (dispersive) spectrometer (with a prism or grating monochromator)?

C. What is the purpose of the interferometer in the FTIR spectrometer?

D. List the types of sample preparation techniques used for analysis with an FTIR spectrometer and conventional/dispersive spectrometer and explain when they would be used.

**6.3.3. Optical Rotation/Polarimeter (USP <781>)**

**6.3.3.1. Objective**

To review the theory, instrumentation and proper techniques for optical rotation sample preparation and analysis in the drug laboratory (topics outlined below). The student is expected to read and become familiar with the following techniques as described in the USP, other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Theory

B. Instrumentation

C. Sampling Techniques

D. Operation of Instrument
6.3.3.2. Exercises

A. Check instrument calibration with solid phase calibrator.

B. For the following exercises use product 8. ‘Dextrose’, identified in Attachment A.
   1. Dextrose - Assay (use procedure for Dextrose Injection), part 8.13

6.3.3.3. Questions

A. Describe polarimetry and the types of products for which it is used.

B. What is the purpose of the solid phase calibration cell and how is it used?

C. What is the general equation used in polarimetry and how does temperature effect polarimeter readings?

6.3.4. Chromatographic Techniques

Chromatography is a physical method of separation in which the components to be separated are distributed between two phases, one of which is stationary (stationary phase) while the other (the mobile phase) moves in a definite direction. The ultimate limits in efficiency, for all chromatography (and all separations), are set by the rates of mass transport within the system. A chromatographic system typically consists of several components.

6.3.4.1. Column Chromatography (USP <621>)

6.3.4.1.1. Objective

To acquaint the analyst with the underlying principles of column chromatography as a basis of all chromatographic techniques used for drug analysis (topics outlined below). The student is expected to read and become familiar with the following techniques as described in the USP, other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Theory

B. Column Types
   1. Celite or Cellulose packed in Glass
   2. Solid Phase Extraction Columns (SPE) – Sep-Pak
   3. Gel
   4. Ion Exchange
C. Sampling Techniques

6.3.4.1.2. Exercises (Do one of the two depending on equipment located in the laboratory)

A. See Laboratory Information Bulletin (LIB) # 3357 and # 2571. Prepare a glass column packed with Solka-Floc material. Separate a color sample product such as grape juice or a mixed standard using the column and method cited. Collect each color and determine their identity using UV-Vis Spectrophotometry.

B. See LIB # 3420 and # 2610. Separate a color sample product such as grape juice or a mixed standard using the column and method cited. Collect each color and determine their identity using UV-Vis Spectrophotometry.

6.3.4.1.3. Questions

A. When and why would someone use column chromatography?

B. (To be done at completion of each chromatography sections.). Prepare a chart, comparing and relating each of the techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling and sampling techniques, automation, accuracy and quantitation.

6.3.4.2. Thin Layer Chromatography (TLC) (USP <621> and <201>)

6.3.4.2.1. Objective

To acquaint the analyst with the underlying principles of Thin Layer Chromatography, (a form of planar chromatography) and the equipment and techniques used for presumptive identification/semi-quantitation of drug samples (topics outlined below). The student is expected to read and become familiar with the following techniques as described in the USP or other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Theory

1. Definitions of Terms
   a. Adsorbent
   b. Solvent front
   c. Rf value
d. Origin

e. Eluent

B. Types

1. Silica Gel
   a. Binders
   b. Fluorescent Additives

2. Cellulose

3. High Performance (HPTLC)

C. Sampling Techniques

D. Application Techniques

6.3.4.2.2. Exercises

A. For the following exercises use product 5. ‘Acetaminophen Oral Solution’ identified in Attachment A.
   1. Identification Test B. <201>, part 5.1

B. Spot above sample or standard at several orders of magnitude of concentration. For example, 1ul, 2ul, 5ul, 10ul, 20ul, 50ul, 100 ul, 200ul, and 500ul.

6.3.4.2.3. Questions

A. TLC is a qualitative method. How can someone use this technique as a semi-quantitative tool? As a quantitative tool?

B. The exercise uses UV light as a visualizing tool. What other visualizing tools are commonly used for TLC?

C. In exercise 2 above, what was the smallest spot seen? In the larger spots, were other ‘breakdown’ or ‘related substances’ spots seen in the chromatogram? If found, can the quantity be estimated based on the size of the smaller standard spots?

D. (To be done at completion of each chromatography sections). Prepare a chart, comparing and relating each of the techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling, and sampling techniques, automation, accuracy, and quantitation.
6.3.4.3. Gas Chromatography (GC) (USP <621>)

6.3.4.3.1. Objective

To present theory, instrumentation, parameters, and techniques for GC pharmaceutical analysis (topics outlined below). The student is expected to read and become familiar with the following techniques as described in the USP, other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Theory/Applications

B. Instrument Components

1. Columns
   a. Packed Columns
   b. Capillary Columns

2. Gases

3. Temperatures
   a. Isothermal
   b. Temperature Program

4. Injection
   a. Packed
   b. Split/Splitless

5. Detectors
   a. FID
   b. ECD
   c. Nitrogen/Phosphorus
   d. MS
   e. Other

6. Data Handling

7. Calculation Techniques

C. Sampling Techniques

1. Direct Injection Techniques

2. Autoinjection

For the most current and official copy, check QMiS.
Headspace Sampling

D. Operation

E. Quality Assurance (System Suitability)

6.3.4.3.2. Exercises

A. For the following exercises use product 5. 'Acetaminophen Oral Solution' identified in Attachment A.
   
   1. Alcohol Content (if alcohol not already present spike at a 5% concentration) Method 2 <611> (packed column GC analysis), part 5.3 or Method 11 b <611> (capillary column)

B. For the following exercises use either product
   
   1. Product 10 'Glycerin' - Organic Impurities Procedure 1: Related Compounds [Capillary column GC analysis], part 10.3
   
   2. or include product 7. 'Saccharin' Limit of Toluenesulfonamides - [Capillary column GC analysis], part 7.6

C. Calculate the results using both area and peak height calculations (electronically or manually) and compare the results.

6.3.4.3.3. Questions

A. What type of products can be tested by GC? What products cannot be tested? Describe a GC method that can analyze products that normally cannot be tested by a GC method.

B. Describe how a Flame Ionization Detector (FID) works. Describe at least three other GC detectors commonly used. Which detector is similar to FID and how is it used?

C. Describe capillary GC and how it differs from packed column GC. What are the advantages and disadvantages of each technique?

D. When is it appropriate to use temperature programming? What are the advantages of using temperature programming.

E. GC commonly uses four different gases. Air, Nitrogen, Helium and Hydrogen. What is the purpose of each gas, how is it used and at what flow rates?

F. (To be done at completion of each chromatography sections). Prepare a chart, comparing and relating each of the techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling, and sampling techniques, automation, accuracy, and quantitation.

For the most current and official copy, check QMiS.
6.3.4.4. **High Performance Liquid Chromatography (HPLC) (USP <621>)**

6.3.4.4.1. **Objective**

To present theory, instrumentation, parameters, and techniques for HPLC pharmaceutical analyses (outline below). HPLC has become the most common and important analytical tool in the modern drug laboratory. The student is expected to read and become familiar with the following techniques as described in the USP or other literature, or through discussion with the trainer. The trainer is expected to provide explanations and devise simple exercises for the student to practice the techniques.

A. Theory/Application

B. Instrument Components

1. Columns
   a. Normal Phase Columns
   b. Reverse Phase Columns
   c. Ion Exchange Columns
   d. Guard Columns
   e. FAST Columns
   f. Specialty Columns
   g. USP Classifications

2. Column Parameters
   a. Packings
   b. Size (both column and packing)
   c. Dimensions

3. Mobile Solvents
   a. Aqueous and non-aqueous
   b. Buffers
   c. PIC and ion-pair modifiers
   d. Solvent Programming - Gradient

4. Injection
   a. Techniques
   b. Autoinjection

For the most current and official copy, check QMiS.
5. Solvent Delivery (Pumps)
   a. Isocratic
   b. Solvent Program

6. Detectors
   a. UV
   b. Electrochemical
   c. MS
   d. Other Specialty

7. Data
   a. Integration
   b. Data Protection

C. Sampling Techniques
   a. The need for clean samples and their preparation

D. Quality Assurance (System Suitability)

6.3.4.4.2. Exercises

A. For the following exercises use product 5. ‘Acetaminophen Oral Solution’ identified in Attachment A.
   1. Assay. MeOH/H2O, Simple Isocratic Systems, part 5.4;
   2. HPLC Identification Test A, part 5.1; and
   3. pH <791> for product, part 5.2.

B. For the following exercises use product 4. ‘Acetaminophen and Caffeine Tablets’ identified in Attachment A.
   1. Assay, HPLC multi-component with IS, part 4.4,
   2. HPLC Identification, part 4.1, and
   3. Dissolution and Uniformity of Dosage Units (HPLC), parts 4.2 and 4.3. (optional)

C. For the following exercises use product 3. ‘Aspirin Tablets’ identified in Attachment A.
   1. Assay, HPLC ion-pair system, part 3.5;
   2. Limit of Free Salicylic Acid, HPLC, part 3.4;
3. Uniformity of Dosage Units (HPLC), Identification test A, (optional); and
4. Identification Test B, part 3.1

D. For the following exercises use product 9. 'Naltrexone Hydrochloride Tablets' identified in Attachment A.

1. Assay, HPLC gradient system, part 9.4;
2. Identification, part 9.1; and
3. Optional – Uniformity of Dosage Units, part 9.3

6.3.4.4.3. Questions

A. Describe a typical ‘basic' HPLC system and the purpose of each component.

B. What is the difference between normal phase and reverse phase? List at least three column types for each phase.

C. For the chromatograms obtained in exercise 2 ‘Acetaminophen and Caffeine Tablet' calculate the following for each of the peaks: Retention Time, Retention Volume, Relative Retention Time to IS, Capacity Factor, Resolution, Tailing, Theoretical Plates, Height Equivalent Theoretical Plate, Peak Widths at base, half height, and 5% height. Also calculate one set of sample results using both peak area and peak height calculations. Are the results different? If so, explain why differences may result.

D. What is the purpose of the internal standard used in exercise 2? Calculate one set of sample results without using the internal standard. Are the results different? If so explain why differences may result.

E. When and why would gradient elution be used in HPLC? What is the effect of temperature on HPLC? Would temperature programming such as found in GC be effective for HPLC?

F. (To be done at completion of each chromatography sections). Prepare a chart, comparing and relating each of the techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling and sampling techniques, automation, accuracy, and quantitation.

6.3.5. Other Specialized Techniques

There are many specialized techniques used in pharmaceutical chemistry analysis. With the exception of dissolution, most of these techniques are
unique to the specialty laboratory or have not found wide recognition and thus are not usable for a basic training outline. All these techniques would be considered in advanced drug training. These other techniques will be mentioned by category only and could be expanded if the training laboratory has a need for this area of analytical techniques.

6.3.5.1. Dissolution (USP <711>)

6.3.5.1.1. Objective

Dissolution is a technique commonly employed for tablet and capsule-type drug products. Modifications of the technique allow its use for other dosage forms such as patches, creams, and ointments. USP Apparatus 1 and 2 are covered in this section since these are the apparatus found in most drug laboratories.

A. Theory
B. Instrumentation
   1. USP Apparatus 1 (basket)
   2. USP Apparatus 2 (paddle)
   3. Other USP Apparatus (discussion only)
C. Calibration
   1. Mechanical Calibration
      a. Temperature
      b. Rotation Speed
      c. Vibration
      d. Height (positioning)
      e. Wobble
      f. Centering
      g. Level
   2. USP Performance Verification Test
D. Operation – Sampling
   1. Single Time period
   2. Profile Sampling
   3. Extended Release Products
E. Autosampling Techniques

For the most current and official copy, check QMiS.
6.3.5.1.2. Exercises

A. Perform the dissolution performance verification test in accordance with the current USP procedure.

B. For the following exercise use product #3. ‘Aspirin Tablets’ identified in Attachment A.
   1. Dissolution, Apparatus 1 @ 50 rpm – 500 mL pH 4.5 buffer – UV determination, part 3.2.

C. For the following exercise use product #4. ‘Acetaminophen and Caffeine Tablets’ identified in Attachment A.
   1. Dissolution, Apparatus 2 @ 100 rpm – 900 mL water – HPLC determination, part 4.2.

D. For the following exercise use product #2. ‘Ascorbic Acid Tablets’ identified in Attachment A.
   1. Dissolution, Apparatus 2 @ 50 rpm – 900 mL water ‘Procedure for pooled sample’ – titration determination, part 2.3.

6.3.5.1.3. Questions

A. What parameters need to be checked and corrected before dissolution is run? Describe the effect that each would have on an analysis.

B. Exercise 2 demonstrates a profile analysis. When would this technique be used? For what type of products could this technique be used? Find a monograph in USP that uses a profile type analysis.

C. Describe the reason and procedure for removing air from the dissolution media.

D. Why not use water for all dissolution media and have constant paddle/basket rotation speed for all determinations?

E. Compare in-vitro dissolution results with in-vivo clinical studies? Explain the answer.

6.3.6. Advanced Techniques

To be developed as advanced training on an as-needed basis: (USP <___> identifies sections found in General Chapters, General Tests, and Assays found in the USP).

A. Particulate Matter in Injections (USP <788>)

B. Capillary Electrophoresis (CE) (USP <1053>)

C. Ion Chromatography (USP <1065>>)

For the most current and official copy, check QMiS.
D. Atomic Absorption Spectrophotometry (AA) (USP <852>)
E. Fluorescence Spectroscopy (USP <853> and <1853>)
F. GC/Mass Spectrometry (USP <621> and <736>)
G. LC/Mass Spectrometry (USP <621> and <736>)
H. Nuclear Magnetic Resonance (NMR) (USP <761>)
I. Refractive Index (USP <981>)
J. Differential Scanning Calorimetry (DSC) and Thermal Gravimetric Analysis (TGA) (USP <891>)
K. Polarography (USP <801>)
L. Immunological Test Methods (USP <1106>)
M. Osmolarity (USP <785>)
N. Dissolution Apparatus III to VII (USP <711> and <724>)
O. Drug Release (Extended Release, Delayed Release and Transdermal Systems) (USP <724>)

P. Guidance and Procedures for characterization of biotechnology-derived articles by CE, Biotechnology-Derived Articles – Isoelectric Focusing (USP <1053> and <1054>)
Q. Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests (USP <601>)
R. Plasma Spectrochemistry (USP <730>)

6.4. Inspections/Investigations

All analysts are to participate in at least one inspection prior to attending the FDA sponsored FDA Law and Evidence Development Course. In addition, analysts in drug specialty laboratories are provided specialized training in the inspection of pharmaceutical laboratories as defined in Current Good Manufacturing Practices (cGMPs) under 21 CFR Parts 210 and 211. This training program is developed according to the needs of the laboratory. Analysts should become familiar with sections of the Investigations Operations Manual (IOM) that involve preparing for and conducting team inspections. An example of training is as follows:

A. Types of Inspections
   1. GMP
   2. Pre-Approval
   3. Post Approval
4. Contract Laboratory
5. Private Laboratory (Import work)
6. Clinical Laboratory
7. Foreign Inspections
B. Preparing for Team Inspections
C. How to start an inspection (482)
D. What to look for in the Laboratory
   1. FDA Inspection Guides
E. Evidence Development
   1. Documentation and Affidavits
   2. Photography
F. Prepare a 483
G. Prepare an EIR

7. Glossary/Definitions
   None

8. Records
   None

9. Supporting Documents
   None

For the most current and official copy, check QMiS.
10. Document History

<table>
<thead>
<tr>
<th>Revision #</th>
<th>Status* (D, I, R)</th>
<th>Date</th>
<th>Author Name and Title</th>
<th>Approving Official Name and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3</td>
<td>R</td>
<td>11/03/2005</td>
<td>LMEB</td>
<td>LMEB</td>
</tr>
<tr>
<td>1.4</td>
<td>R</td>
<td>01/17/2008</td>
<td>LMEB</td>
<td>LMEB</td>
</tr>
<tr>
<td>1.5</td>
<td>R</td>
<td>02/02/2010</td>
<td>LMEB</td>
<td>LMEB</td>
</tr>
<tr>
<td>1.6</td>
<td>R</td>
<td>02/05/2012</td>
<td>LMEB</td>
<td>LMEB</td>
</tr>
<tr>
<td>1.7</td>
<td>R</td>
<td>02/13/2014</td>
<td>LMEB</td>
<td>LMEB</td>
</tr>
<tr>
<td>02</td>
<td>R</td>
<td>05/05/2020</td>
<td>LMEB</td>
<td>LMEB</td>
</tr>
</tbody>
</table>

* - D: Draft, I: Initial, R: Revision

11. Change History

<table>
<thead>
<tr>
<th>Revision #</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3</td>
<td>Table of Contents – Added 3.6 Appendix 2; added 3.8 Revised Section 3.1, 3.2 B., 3.3 B. 5., 3.4.1, 3.4.2.1 A., B. &amp; C., 3.4.2.2, 3.4.2.2 I. B., 3.4.2.2 II. B., 3.4.2.2 III., 3.4.2.3 III. B. &amp; IV. B., 3.4.2.4 I. A. &amp; II., 3.4.3, 3.5, 3.6 Appendix 1 &amp; 3; added 3.6 Appendix 2.</td>
</tr>
<tr>
<td>1.4</td>
<td>3.1, 3rd para, last sentence – Deleted “altogether” 3.2, 3rd para - Changed “diethyl” to “diethylene” 3.3 A. 1st para – added “or pressure” after high performance 3.3 B. 1., 4th para – revised 3.3 B. 6. – revised 3.3 B. 8. – updated 5th web address 3.3 C. 2. – revised 3.4.2.3 B. 3. – deleted 3.4.2.3 III. C. 2. – added (FID) 3.4.2.4 I. C. 3. – revised 5th sentence 3.5 – deleted 1st para 3.7 – revised 3.3.2, 3.4.2.2. (I) 1. &amp; 5., 3.4.2.2 (II) 4., 3.4.2.3. (III) 1. &amp; 4., 3.4.2.3. (IV) 2., 3.4.2.4 (I).1.</td>
</tr>
<tr>
<td>Revision #</td>
<td>Change</td>
</tr>
<tr>
<td>------------</td>
<td>--------</td>
</tr>
</tbody>
</table>
| 1.5        | 3.3.B. – updated web links in 5., 7., & 8.; added last sentence to 8.  
3.4.2.4 I. A. III. B. – revised  
3.4.2.4 I. B. 1. – revised  
3.4.2.4 I. B. 2. - deleted  
3.5 – updated web links  
Footer – updated web link |
| 1.6        | 3.3 B. 2. – changed “testing” to “review” in second sentence  
3.3 C. 5. – deleted  
3.4 – added last sentence  
3.4.2 I.. A. – added USP reference to bullet 7; deleted bullet 10; added bullets 13 and 14  
3.4.2.I. B. 2. – deleted Disintegration Test from bullet 2  
3.4.2.I. B. 3. – “6” changed to “8” in bullets  
3.4.2.2 II. A. III. – added D. and E.  
3.4.2.3.III B. 1. – changed “Suspension” to “Solution” in 1.; added Method 11 b to bullet  
3.4.2.3 III B. 2. – revised  
3.4.2.3 IV. A. 2. – added 7.; added “Gradient” to C.4.  
3.4.2.3.IV. B.1. – “Suspensions” changed to “Solution”; B change to A, part 5.1 in second bullet; 5.1 deleted in third bullet  
3.4.2.4. I. C – deleted 2.  
3.4.2.4.II. 16. – changed VIII to VII  
Appendix 1 I. – deleted 2.3; changed Apparatus 2 to Apparatus 1 in 3.2; changed Suspension to Solution in 5.; changed 6.1 B. to HPLC; deleted 6.6, 6.7, and 6.8; 7.1 changed to FTIR; 7.6 spelling corrected and changed to FID; deleted 7.10; added “loss on” to 8.5; added <281> to 8.6; 8.12 changed to color from limit test; 9.2 changed from UV to HPLC; added 10.  
Appendix 2 I. – added 4. and changed GC product and test method  
3.7 Answer Key 3.3 3.- answer revised and deleted 4., 5., and 6.  
3.7 Answer Key 3.4.1 1. – first and second sentence revised  
3.7 Answer Key 3.4.2.1 – 3. deleted sentences 3., 4., 5., and the last sentence  
3.7 Answer Key 3.4.2.4. (l) –deleted 2. |
| 1.7        | Header – Division of Field Science changed to Office of Regulatory Science  
7. – Division of Field Science changed to Office of Regulatory Science |

For the most current and official copy, check QMiS.
### Title:
Drug Chemistry Analysis

<table>
<thead>
<tr>
<th>Revision #</th>
<th>Change</th>
</tr>
</thead>
</table>
| 02         | Document revised to current format guidance -numbering  
All references revised accordingly  
Under Introduction:  
ORA U revised to OTED  
Add sample match to sample description in collection report  
Add sample expiry  
Add DQSA information  
Pharmaceutical Products Overview  
Removed Biotechnology Developed Drugs Reference  
Revised Fillers Reference; added Excipient Performance  
Revised Shelf Life PAC; added 88D  
Deleted - “to find” PAC  
Revised Thermometers; add (USP<1118>)  
Revised titrations; added (USP<541>)  
Water Determination Added (USP<731>)  
Deleted Limit Tests (USP<231>) and all subsequent references  
Revised Ultraviolet/Visible Spectrophotometry (USP <857>) and ULTRAVIOLET-VISIBLE SPECTROSCOPY—THEORY AND PRACTICE (USP <1857>)  
Revised. Fourier Transform Infrared Spectrophotometry (FTIR) [USP <854>] and MID-INFRARED SPECTROSCOPY—THEORY AND PRACTICE (USP <1854>)  
Removed and revised Specific rotation reference  
Exercise B revised; added Identification Test B <201>, part 1.1  
Aspirin Uniformity of Dosage, ID A, ID B revised for clarity  
Advanced Techniques  
Added Particulate Matter (USP <788>)  
Revised CE reference; added (USP<1053>)  
Revised AA reference; added (USP<852>)  
Revised Fluorimetry reference; added (Florescence Spectroscopy (USP<853> and <1853>)  
Deleted Electrophoresis  
Deleted Immunoassays; added Immunological Test Methods (USP <1106>)  
Deleted Analytical Biotechnology using CE, HPLC, Isoelectric focusing. (USP <1047>)  
Add Plasma Spectrochemistry (<730>)  
Section 3.5 References renamed as Section 9 Supporting Documents  
Training Sample Section References updated  
Delete and update Training Sample Section references to reflect template numbering changes throughout the document |

For the most current and official copy, check QMiS.
12. Attachments

List of Attachments
Attachment A - Exercise – Practice with Samples ...................................................... 36
Attachment B: Example – Proficiency Samples ............................................................. 41
Attachment C: Statistical Analysis ............................................................................. 43
Attachment D: Answer Key ......................................................................................... 46
Attachment E. Column Chromatography Chart ........................................................... 69
Attachment A - Exercise – Practice with Samples

Training Samples

Training samples may vary and depend on what is available in the laboratory. The training samples, using USP products whenever possible, also demonstrate the trainee’s ability and proficiency in performing regulatory tests. The following were used for the above training program and are examples of products that have been used successfully for training. However, other products may be used that demonstrate the same level of training. Specific tests may not apply based on current laboratory practice or revised monograph requirements. Underlined parts of the following products were not used in the exercises but may be added to complete a full product analysis. Full worksheets are to be generated for each product analyzed. Italicized items 1, 4 & 7 are also proficiency samples. (* also identified as a proficiency test in Appendix 2).

USP < > refers to the General Chapters – General Tests and Assays, General Requirements for Tests and Assays found in the back of the USP/NF

I. Training Samples

1. **Acetaminophen (API)** – USP, current edition, {Section 6.3.1.2.A, 6.3.2.1.2D, 6.3.2.2.2B}
   
   1.1 Identification
      
      Test A: Infrared <197K> *
      
      Test B: UV <197U>
      
      Test C: TLC <201> *
   
   1.2 Melting Range <741>
   
   1.3 Water Method 1 <921> KF Titration *
   
   1.4 Residue on Ignition <281>
   
   1.5 4-Aminophenol in Acetaminophen-Containing Drug Products USP (227) - limit test; intra-monograph test applicable for HPLC (USP <621>)
      
   1.6 Organic Impurities (USP <621> and <1086>) HPLC.
   
   1.7 Assay – UV *
2. **Ascorbic Acid Tablets** – USP, current edition, {Section 6.3.1.2B, 6.3.5.1.2D}
   
   2.1 Assay – titration
   
   2.2 Identification – Test B
       
       Test A – spot test
       
       Test B – color test
       
       Test C – color test
   
   2.3 Dissolution, Procedure for Pooled Sample <711>
   
   2.4 Uniformity of Dosage (Weight Variation)

3. **Aspirin Tablets** – USP, current edition {Section 6.3.4.4.2C, 6.3.5.1.2B}

   3.1 Identification
       
       Test A – retention time
       
       Test B – IR <197K>
   
   3.2 Dissolution <711> Apparatus 1 – UV Det
   
   3.3 Uniformity of Dosage Units <905>
   
   3.4 Limit of Free Salicylic Acid – HPLC
   
   3.5 Assay – HPLC with ion-pair reagent

4. **Acetaminophen and Caffeine Tablets** – USP, current edition, {Section 6.3.4.4.2B, 6.3.5.1.2C}

   4.1 Identification - HPLC
   
   4.2 Dissolution <711> Apparatus 2 - HPLC *
   
   4.3 Uniformity of Dosage Units <905> HPLC
   
   4.4 Assay – HPLC two component with IS *
5. **Acetaminophen Oral Solution** – USP, current edition, {Section 6.3.4.2.2A, 6.3.4.3.2A, 6.3.4.4.2A}

5.1 Identification – FTIR <197K>
   A. HPLC
   B. TLC <201>

5.2 pH <791>

5.3 Alcohol Content (if present) Method II <611>
   (if alcohol not present spike at 5% ethanol)

5.4 Assay – HPLC <621>

6. **Caffeine API** – USP, current edition

6.1 Identification
   A. Infrared Absorption <197M>
   B. HPLC

6.2 Melting Range <741>

6.3 Water, Method III <921>

6.4 Residue on Ignition <281>

6.5 Organic Impurities - HPLC

6.6 Assay – HPLC <621>

7. **Saccharin** – NF, current edition, {Section 6.3.1.2.D, Section 6.3.4.3.2B2}

7.1 Identification – FTIR

7.2 Melting Range <741>

7.3 Loss on Drying <731>

For the most current and official copy, check QMiS.
7.4 Readily carburizable substances <271>
7.5 Residue on Ignition <281>
7.6 Toluene sulfonamides – Column and gas chromatography (FID)
7.7 Benzoic and salicylic acids – chemical test
7.8 Color of Solution
7.10 Assay – Titration *

8. **Dextrose** – USP, current edition, {Section 6.3.1.2.C, 6.3.3.3.2B}

8.1 Identification – color precipitate
8.2 Color of Solution – limits test
8.3 Specific Rotation <781S>
8.4 Acidity – titration
8.5 Water Method III <921> (loss on drying)
8.6 Residue on Ignition <281>
8.7 Chloride <221> - limit test
8.8 Sulfate <221> - limit test
8.9 Arsenic Method I <211> - limit test
8.11 Dextrin – limit test
8.12 Soluble starch, sulfites – color
8.13 Assay - Optical Rotation (Use current USP procedure for Dextrose Injection).

9. **Naltrexone Hydrochloride Tablets** – USP, current edition, {Section 6.3.4.4.2D}

9.1 Identification - HPLC
9.2 Dissolution <711> Apparatus 2 – HPLC Determination

For the most current and official copy, check QMiS.
9.3 Uniformity of Dosage Units – HPLC gradient

9.4 Assay – HPLC gradient

10. Glycerin – USP, current edition, {Section 6.3.4.3.2B, 3.4.2.3 IVB}

10.1 Identification –
   A. FTIR
   B. Limit of Diethylene Glycol and Ethylene Glycol (GC-FID)

10.2 Assay – Titration

10.3 Impurities
   Inorganic Impurities
   Organic Impurities –
   Procedure 1 Related Compounds (GC-FID)
   Procedure 2 – Limit of Chlorinated Compounds
   Procedure 3 – Fatty Acids and Esters

10.4 Specific Gravity <841>

10.5 Water Determination <921>

11. Ascorbic Acid API – USP, current edition, {Section 6.3.1.2B, 6.3.5.2.3D}

11.1 Optical Rotation – <781S>

II. Additional Training Samples as needed:

Additional training samples may be added or substituted to demonstrate and reinforce the analytical procedures listed in the training program.
Attachment B: Example – Proficiency Samples

Proficiency Training Samples for new hires:
The following is designed to show proficiency in 7 technologies commonly used in drug analysis. An analyst should demonstrate the ability to successfully analyze these as a minimum requirement.

Each analyst will complete the following tests to demonstrate proficiency for each of the techniques outlined below with the identified sample.

1. **Acetaminophen API** – ID by FT-IR & TLC, ID/Assay by UV/Vis, and Water (Karl Fischer Titration). (Item 1, Part II Training Samples below for specific information)
2. **Acetaminophen & Caffeine Tablets** – Assay by HPLC and Dissolution with HPLC detection. (Item 4, Part II Training Samples below for specific information. Quantify for both acetaminophen & caffeine.
3. **Saccharin** – Assay by Titration. (Item 7, Part II Training Samples below for specific information)
4. **Glycerin** – Organic Impurities by GC (Item 10, Part II Training Samples below for specific information).
Technology, Product and Method

<table>
<thead>
<tr>
<th>Test Technology</th>
<th>Examples of Product Used</th>
<th>Test Method</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spectroscopy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTIR</td>
<td>Acetaminophen (API)</td>
<td>USP (Identification) USP &lt;197K&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USP &lt;197U&gt;</td>
</tr>
<tr>
<td>UV-Vis</td>
<td>Acetaminophen (API)</td>
<td>USP (Assay) USP &lt;197U&gt;</td>
</tr>
<tr>
<td><strong>Separation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPLC</td>
<td>Acetaminophen &amp; Caffeine Tablets</td>
<td>USP (Assay) USP &lt;621&gt;</td>
</tr>
<tr>
<td></td>
<td>Glycerin (API)</td>
<td>USP (Organic Impurities Procedure 1: Related Compounds) USP &lt;621&gt;</td>
</tr>
<tr>
<td>TLC</td>
<td>Acetaminophen (API)</td>
<td>USP (Identification)</td>
</tr>
<tr>
<td><strong>Misc.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titration</td>
<td>Saccharin (API)</td>
<td>NF (Assay) USP &lt;541&gt;</td>
</tr>
<tr>
<td>Water (Karl Fischer)</td>
<td>Acetaminophen (API)</td>
<td>USP (Water – Method 1) USP &lt;921&gt;</td>
</tr>
<tr>
<td>Dissolution</td>
<td>Acetaminophen &amp; Caffeine Tablets</td>
<td>USP (Dissolution – App. 2) USP &lt;711&gt;</td>
</tr>
</tbody>
</table>

USP and NF (    ) refers to the Test in the Official Monographs for the listed product.

II. **Additional Proficiency Samples as needed:**

Additional proficiency samples may be added or substituted. The products need to include the above ‘Test Type’ and show proficiency in those techniques.
Attachment C: Statistical Analysis

Analytical results observed in the laboratory are to be accurate and reliable based upon statistical principles and by the current Good Manufacturing Practices. ORA LAB Manual Vol. III Section 4, Basic Statistics and Data Presentation, covers statistical analysis in detail and should be reviewed. The following information is supplemental to LAB Manual, Vol. III. sec. 4 and is provided as a summary and a guide.

A. Definitions

Some of the definitions are from the ICH Validation Procedures definitions, which appeared in the Federal Register #60, March 1, 1995, p. 11260.

A. Number of Significant Places: The total number of digits, not counting leading zeros, from the first non-zero digit, to the last digit known with a reasonable confidence.

B. Error: Difference between the expected and the encountered value of some variable.

C. Incertitude: Lack of availability of information about a reading caused by the impossibility of reading closer than a certain readout limit. For example, a digital readout of 22.57, with no digits beyond the second decimal, has incertitude of +/- 0.01.

D. Standard Deviation, \( \sigma = \sqrt{\frac{\sum(x_i-x_{\text{average}})^2}{n-1}} \). See Precision.

E. RSD: Relative standard deviation. The standard deviation divided by the average; usually expressed as percent by multiplying it by 100.

F. Accuracy: The closeness of agreement between the value which is accepted (either as a conventional true value or as an accepted reference value) and the value found.

G. Precision: The closeness of agreement between a series of measurements obtained from multiple sampling under the same conditions. Usually expressed as standard deviation.

H. Repeatability: Precision measured in the same laboratory and under the same operating conditions, over a short period of time.

I. Intermediate precision: Precision within the same laboratory but under different conditions, analysts and equipment.

J. Reproducibility: Precision between different laboratories, such as in collaborative studies.
K. Robustness: The ability of a procedure to remain unaffected by small but deliberate variations in method parameters. It is an indication of reliability during normal usage.

B. Using Significant Digits (see ORA LAB Manual, Vol. III, Sec. 4.3.2 Significant Figures)

Normally, the confidence in the value of a number decreases from the first to the last digit. Thus, if a volume measurement gives 10.567 mL we may be quite confident that the value is close to 10 mL but less confident about the decimal "5", still less about the "6" and not sure at all about the "7". In this case, the digit 7 is called the least significant digit (LSD). The number 10.567 is said to have 5 significant digits. The number of significant digits is obtained counting all digits that give reasonable confidence, not including leading zeros. For example, 0.0031 has two significant digits.

The rules of significant digits are rules of data communication. Only report the digits in which there is confidence. The non-significant ones are eliminated according to the rules outlined below. Data in process are kept with an extra significant figure and rounded to the correct significant figures for the final answer. A good rule is using five digits throughout but reporting at the end with the correct number of significant digits.

Note: Do not confuse significant digits, with significant places. The latter depend on the units used and the concept should be avoided in this context. For example, 12.53 cm = 125.3 mm. Both have four significant digits, but different number of significant places (two and one respectively).

C. Performing Rounding (see ORA LAB Manual, Vol. III, Sec. 4.3.1 Rounding of Reported Data)

The procedure (see USP General Notices 7.20. Rounding Rules) for rejecting the digits beyond the least significant digit, LSD, is the following:

1. Establish the position of the LSD.

2. If the digit to the right of the LSD is less than 5, eliminate all remaining digits after the LSD.

3. If the next digit is larger than or equal to 5, increase the LSD by one and eliminate all the digits beyond the LSD.

Remember: The calculations are always retaining an extra significant figure over the significant ones. Rounding should be done only at the end to the correct significant figures.
D. Using Average and Standard Deviation (see ORA LAB Manual, Vol. III, Sec. 4.2.2 Error and Deviation; Mean and Standard Deviation)

The average and standard deviation are estimates after the fact. This means that a number of measurements are first made and then their statistical properties are obtained from the analysis of the set of measurements. Calculations:

\[
\text{Average} = \frac{\sum x_i}{n}, \text{Sum of all data divided by the number of data}
\]

\[
\text{Variance} = \frac{\sum (x_i - \text{average})^2}{n-1} \text{ The number n-1 is the number of data minus one.}
\]

\[
\text{Standard deviation, } \sigma = \sqrt{\frac{\sum (x_i - \text{average})^2}{n-1}}
\]

\[
\%\text{RSD} = \text{Relative Standard Deviation} = \frac{\text{standard deviation}}{\text{average}} \times 100
\]
Attachment D: Answer Key

6.1 Methodology

1. What are the five most significant items of information in the USP "General Notices?" Compare the "General Notices" with the introductory chapter in the Official Methods. This is a subjective answer, but the answer could include the following: The use of "Official" and "Official Article"; Significant Figures and Tolerances; Reference Standards/Reagents; Tests and Assays; Preservation, Packaging, Storage and Labeling (especially storage temperature); Weights and Measures; and Concentrations. The "Guide to General Chapters" contains information regarding procedures used throughout the USP; the General Notices serves as a general guidance document.

2. Using the current USP, find the Dissolution procedure for Ascorbic Acid Tablets and how does it differ from most other Dissolution procedures? Ascorbic Acid Tablets monograph uses a pooled sample procedure where equal volumes of each vessel are pooled, and the one-pooled solution is assayed. The assay procedure is performed on the solution from each vessel for most Dissolution procedures.

3. Where in the USP are the listings for column types used in HPLC and GLC? How are they designated? There is a separate section “Chromatographic Columns”. This lists both the column used for each general chapter or monograph and the column types for both HPLC and GLC. HPLC is listed as packings with a letter designation beginning with ‘L’. GLC is listed as phases with a letter designation beginning with ‘G’.

4. What does the term “Official Compendium” mean? Name the three major types of “official” methods used by FDA. "The term 'official compendium' means the official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, official National Formulary, or any supplement to any of them." See Section 9F Chapter II Definitions Sec. 201 (j), three major types of “official” methods used by FDA are the (1) United States Pharmacopeia, (2) AOAC Official Methods. (3) FDA approved New Drug Application or Abbreviated New Drug Application methods.

Pharmaceutical Products Overview

1. When would you use a USP standard and when would you use a working standard? What is needed for working standards that is not needed for USP standards and why? The USP standard when available is to be used for the analysis of all USP products. Working standards are used for products and dosage...
forms not found in the USP or when an USP standard is not available. The purity and identity of all working standards are to be verified before use to assure that the standard is sufficiently pure, and it is the correct material. The standard purity is to be used in the assay calculations. The USP standard is assumed to be 100% unless otherwise stated on the label.

2. What is the procedure in the laboratory for obtaining USP standards? NIST standards? Controlled drug standards? The answer to this question is dependent on the District and Laboratory policy. The trainee is to describe this procedure and reference the Laboratory’s SOP.

3. Describe the differences between an immediate release tablet/capsule, an extended release tablet/capsule and a delayed release tablet. How would one classify transdermal patches and implants? Immediate release tablet and capsules release the active ingredient within a small period of time, typically less than 30 minutes. Extended Release tablets release the active ingredient at a sustained and controlled release rate over a period of time. Typically, extended release tablets and capsules release their ingredient with time periods of 8 hours, 12 hours, 16 hours, and 24 hours. Delayed Release tablets release the pharmaceutical dosage after a set time. These are frequently enteric coated to prevent release in the stomach thus release the dosage in the intestinal track. Transdermal patches and implants would be classified as extended release products but release the dosage over a much greater period of time such as weeks or months.

4. What items would likely be found in compressed tablets and what is their purpose? In capsules? Name at least three items.
   - Active Ingredient – supplies pharmacological dose: any drug product.
   - Diluents (Fillers) – provide bulk: lactose, calcium phosphate, microcrystalline cellulose.
   - Binders – impart cohesive properties: starch, povidone (PVP).
   - Lubricants – reduce mechanical friction and prevent tablets from sticking to punches and dies: magnesium stearate.
   - Glidants (Flow Agents) – promotes free flowing characteristics: colloidal silicon dioxide, talc.
   - Disintegrants – enable tablets to break apart in aqueous environments: starch, crospovidone (PVP-XL), croscarmellose, Na starch glycolate.
   - Capsule – holder for active and filler materials: gelatin.

5. Describe where you would find the PAC code for a product All FDA collected samples appear in FACTS, which lists the PAC codes and the type of sample. PACs for the various programs are located in the Compliance Program Guidance.
Manual (CPGM). The CPGM frequently provides additional sample information including methodology to be used for the products being analyzed.

Basic Analytical Techniques

1. **What other standard technique can be used for determining the Melting Range and why are these used? What standards are used for calibration of the Apparatus?** A USP Reference Standard or National Formulary Reference Standard corresponding to an authentic specimen of the substance being tested is added in equal parts to the substance until an intimate mixture is obtained. Agreement of observations on the authentic and the mixture provides reliable evidence of chemical identity. USP Melting Point Reference Standards are used for calibration of the apparatus. There are six such standards: Acetanilide, Caffeine, Phenacetin, Sulfanilamide, Sulfapyridine and Vanillin. The one that melts nearest the expected melting temperature of the substance under test is used.

2. **Why are limit and qualitative tests added to USP monographs? Compare the limit tests of the Acetaminophen product with those found in the Dextrose (including those not run). Which tests use the same method?** USP monographs serve to define the identity, strength, quality, and purity of the substances for which they are written. Limit and qualitative tests are part of that determination. Tests for the presence of foreign substances and impurities are provided to limit such substances to amounts that are unobjectionable. Both monographs use the same tests for residue on ignition <281>, . Acetaminophen also has limit tests for water (<921>Method I), Limit tests for Organic Impurities (HPLC) - sulfide, free p-aminophenol, and p-chloroacetanilide. Dextrose has limit tests for water (<921>Method I), dextrin and soluble starch sulfites.

3. **Both the Acetaminophen product and Caffeine have a method for Water. What is the difference between the two methods? Can the Acetaminophen method be used for Caffeine? Can the Dextrose method be used for Acetaminophen? Explain the answers.** The method used for water determination in Acetaminophen is titrimetric. There is a quantitative reaction of water with an anhydrous solution of sulfur dioxide and iodine in the presence of a buffer, which reacts with hydrogen ions (Karl Fischer Reagent – sulfur dioxide & iodine dissolved in pyridine & methanol). A gravimetric method is used for water determination in Caffeine. Caffeine is dried at 80 degrees for 4 hours. The hydrous form loses between NMT 8.5% of its weight. The anhydrous form loses not more than 0.5% of its weight. The method for Acetaminophen and Caffeine are not interchangeable because one must account for the water of hydration.

7.2.2.(I) Ultraviolet/Visible Spectrophotometry

For the most current and official copy, check QMiS.
1. Define: absorbance, absorptivity, molar absorptivity. (See USP<857> for more information.)

Beers Law supplies the terms: \( \log_{10} \left( \frac{1}{T} \right) = A = abc \)

- Absorbance: \([A]\) is the logarithm, to the base 10, of the reciprocal of the transmittance \((T)\).
- Absorptivity: \([a]\) – the quotient of the absorbance \((A)\) divided by the product of the concentration of the substance \((c)\) expressed in grams per liter, and the absorption path length \((b)\) in cm.
- Molar Absorptivity: \([\text{Symbol like a rounded capital E}]\) -- the quotient of the absorbance \((A)\) divided by the product of the concentration, expressed in moles per liter, of the substance and the absorption path length in cm. It is also the product of the absorptivity \((a)\) and the molecular weight of the substance.

2. What are the typical cell size, specimen concentration and absorbance range used in the analysis of a substance in the UV or visible range?

- Typical cell size (path) is 1 cm.
- For many pharmaceutical substances ‘concentrations of about 10 ug of the specimen per ml often will produce absorbances of 0.2 to 0.8 in the ultraviolet or the visible region.’ Ref. USP <857>.

3. What do the expressions "similar preparation" and "similar solution" indicate (as used in tests and assays involving spectrophotometry in the USP)? The expressions "similar preparation" and "similar solution" indicate that the reference specimen, generally a USP Reference Standard, is to be prepared and observed in a manner identical for all practical purposes to that of the test specimen. Ref. USP <857>.

4. What do the expressions "concomitantly determine" and "concomitantly measured," indicate (as used in tests and assays involving spectrophotometry in the USP)? The expressions "concomitantly determine" and "concomitantly measured" indicate that the absorbances of both the solution containing the test specimen and the
solution containing the reference specimen, relative to the corresponding test blank, are to be measured in immediate succession. Ref. USP <857>.

5. Good practice demands that comparisons be made at the wavelength at which peak absorption occurs. What difference in nm for the wavelength specified in the USP monograph is considered acceptable? If the difference is more than +/- 1 nm from the specified wavelength, re-calibration of the instrument may be indicated. Ref. USP <857>.

7.2.2(II) Fourier Transform Infrared Spectrophotometry (FTIR)

1. **What is FTIR?** A computerized process in which the source of energy is sent through an interferometer (instead of a monochromator) and onto a sample which is irradiated. An interferogram (intensity vs. time spectrum) is obtained, which has the characteristics of a spectrum. A computer mathematically converts the (intensity vs. time) spectrum (fourier transform) into an (intensity vs. frequency) fourier transform infrared spectrum.

2. **What is the advantage of an FTIR spectrometer (interferometer) over a conventional (dispersive) spectrometer (with a prism or grating monochromator)?**

<table>
<thead>
<tr>
<th>Conventional/Dispersive</th>
<th>Interferometer</th>
</tr>
</thead>
<tbody>
<tr>
<td>A large number of moving parts</td>
<td>Only the mirror is in motion</td>
</tr>
<tr>
<td>Requires 7 1/2 minutes to 30-minutes for one scan</td>
<td>Produces a spectrum in as little as 1 second</td>
</tr>
<tr>
<td>Slow scan speed</td>
<td>Rapid scan speed</td>
</tr>
<tr>
<td>To improve resolution adjust slits</td>
<td>No slits in the system to define resolution</td>
</tr>
<tr>
<td>No internal reference for frequency accuracy</td>
<td>Laser provides an internal calibration system with frequency accuracy</td>
</tr>
<tr>
<td>Stray light within the instrument</td>
<td>No equivalent to stray light</td>
</tr>
<tr>
<td>Thermal problems because sample is close to IR source</td>
<td>Sample further removed from the IR source</td>
</tr>
<tr>
<td>IR radiation by sample is viewed by the detector</td>
<td>Emitted radiation by the sample is not viewed by the detector</td>
</tr>
</tbody>
</table>

For the most current and official copy, check QMiS.
3. **What is the purpose of the interferometer in the FTIR spectrometer?** The interferometer replaces the conventional monochromator so that energy throughput is inherently greater (no slits) and all wavelengths present reach the detector during the entire time needed to observe a spectrum. The interferometer is coupled to a detector and a computer that reduces the data to an ordinary spectral curve faster.

4. **List the types of sample preparation techniques used for analysis with an FTIR spectrometer and conventional/dispersive spectrometer, and explain when they would be used.**

   - Mulls formed by grinding the compound and dispersing it in mineral oil (nujol). The oil/sample mixture is then placed between salt plates and pressed together.
     - Poor solubility in a useful solvent and saving of time in sampling handling.
   - Gases and vapors in gas sample cells produce spectra, which differ fundamentally from those observed in a condensed state (solids, liquids, solutions).
     - Sample is to be in a gaseous state that can be transferred to a gas sample cell.
   - Solutions by dissolving the compound (liquid or solid) in a solvent and placing it in a sealed liquid cell.
     - Sealed cell is perhaps the simplest technique to use for liquids with viscosities less than or similar to water.
   - KBr discs (pellets) prepared using a press.
     - A dried powdered or crystalline sample is ground with KBr.
   - Attenuated Total Reflectance (ATR)
     - A solid sample place *in situ* on diamond/crystal center.

7.2.2(III) **Optical Rotation/Polarimeter**

1. **Describe polarimetry and the types of products for which it is used.** Polarimetry is the measurement of optical rotation. Many pharmaceutical substances are optically active in the sense that they rotate an incident plane of polarized light so that the transmitted light emerges at a measurable angle to the plane of the incident light. Ref. USP<781>. Pharmaceutical products that show a dextrorotatory, or (+) optical isomers, and levorotatory, or (-) optical isomer. The products that show such optical rotatory power are chiral.

2. **What is the purpose of the solid phase calibration cell and how is it used?** The solid phase calibration cell is used for checking the calibration of the polarimeter. This
calibrator consists of a plate of quartz mounted in a holder perpendicular to the light path. The calibrator standard readings are traceable to NIST. The cell replaces the need to prepare Dextrose and Sucrose solutions that also can be used for calibration. The solid phase calibration cell is stabilized to a temperature of 25°C and placed in the instruments cell holder. The degree of rotation of the cell can be read directly on the instruments readout system.

3. What is the general equation used in polarimetry and how does temperature affect polarimeter readings? The general equation for polarimetry is $\left[ \alpha \right]^\lambda$ where ‘$\alpha$’ is specific rotation at ‘$t$’ temperature, $\lambda$ wavelength, which equals $100a/lc$ where ‘$a$’ is the observer rotation in degrees, ‘$l$’ is the path length in decimeters and ‘$c$’ is the concentration in grams per 100 ml. Temperature is in the equation and has a direct effect on the measured specific rotation. Temperatures need to be maintained within 0.5°C of the stated value in the USP for the calculations to be valid for a measured product.

7.2.3(I) Column Chromatography

1. When and why would someone use column chromatography? Column chromatography offers a wide choice of stationary phases and is useful for the separation of individual compounds, in quantity, from mixtures." Ref. USP <621>. This technique is used for color analysis and when large quantities of purified materials are needed.

2. (To be done at the completion of each chromatography sections.). Prepare a chart, comparing and relating each of techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling and sampling techniques, automation, accuracy, and quantitation. See Attachment E

7.2.3(II) Thin Layer Chromatography (TLC)

1. TLC is a qualitative method. How can someone use this technique as a semi-quantitative tool? As a quantitative tool? A visual comparison of the size of the spots may serve for semi-quantitative estimation. Quantitative measurements are possible by
means of densitometry, fluorescence, and fluorescence quenching; or the spots may be carefully removed from the plate, followed by elution with an effective solvent and spectrophotometric measurement. Ref. USP <621>.

2. The exercise uses UV light as a visualizing tool. What other visualizing tools are commonly used for TLC? The spots produced by paper or thin-layer chromatography may be located by: (1) direct inspection if the compounds are visible under white or either short-wavelength (254 nm) or long-wavelength (360 nm) UV light; (2) inspection in white or UV light after treatment with reagents that will make the spots visible. Ref. USP <621>.

3. In exercise 2 above, what was the smallest spot seen? In the larger spots, were other ‘breakdown’ or ‘related substances’ spots seen in the chromatogram? If found, can the quantity be estimated based on the size of the smaller standard spots? (Result from experiment reported here.) Most of the USP monographs that use the TLC technique for chromatographic purity call for preparing a reference solution with a known concentration, usually a low concentration. For example, if a standard of about 2ug is prepared and a breakdown spot is observed, an analyst can estimate the quantity as “NMT 2 ug” if the Rf and the intensity of the secondary spot are close to the values of the reference standard solution.

4. (To be done at completion of each chromatography section.) Prepare a chart, comparing and relating each of techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling and sampling techniques, automation, accuracy, and quantitation. See Attachment E

7.2.3(III) Gas Chromatography (GC)

1. What type of products can be tested by GC? What products cannot be tested? Describe a GC method that can analyze products that normally cannot be tested by a GC method. GC is a chromatographic technique that can be used on any pharmaceutical product that contains volatile organic compounds of interest. Typical tests may include assay, impurity testing and organic volatile impurity analysis. The product is to be volatile above the lower temperature limit of the stationary phase and below the upper limit of the stationary phase. Products which are not volatile organic compounds cannot be tested without further treatment. For non-volatile compounds (for example sugars) and thermally labile compounds (for example antibiotics)
derivatization can be used to transform normally non-volatile or thermally unstable compounds to a volatile compound usable for GC.

2. Describe how a Flame Ionization Detector works. Describe at least three other GC detectors commonly used. Which detector is similar to FID and how is it used?
   - A FID detector consists of an air/hydrogen flame and a collector electrode. Ions collected produce an electrical signal.
   - Electron-Capture detector (contains a radioactive source of ionized radiation) is very sensitive for compounds containing halogens and nitro groups.
   - Thermal Conductivity detector (employs a heated wire placed in the carrier gas stream) is used for all volatile compounds but has very low sensitivity. This is sometimes considered to be the universal detector since it can detect most volatile compounds regardless of structure.
   - Nitrogen-Phosphorus or alkali flame-ionization detectors (contains a thermionic source such as alkali-metal salt or rubidium glass bead) are very sensitive for organic nitrogen or phosphorus compounds but have low sensitivity for other hydrocarbons.
   - Mass Spectrometer detector is used to identify ion fragments of the parent molecule. This is a very sensitive detector that can give molecular structural information for the compound of interest.
   - The Nitrogen Phosphorus Detector is a variant of the FID. If the same sample and column are used with an FID and NPD, the same chromatogram will be produced except the NPD will ignore the hydrocarbon solvent and other non-nitrogen containing components and produce a much simpler chromatogram. Used for nitrogen containing drugs.

3. Describe capillary GC and how it differs from packed column GC. What are the advantages and disadvantages of each technique?
   - Capillary GC columns are long (25 - 50 meters), thin (0.18 to .53mm ID) fused silica columns with higher separation efficiency (more theoretical plates) and superior resolution than that of a packed GC column (typically 2 meters long and ¼ inch diameter).
   - Advantages are their high efficiency and sturdiness. They are easy to handle and do not break as easily as glass columns. The capillary column is widely used for complex mixtures because of their superior resolution
   - The disadvantages of capillary GC is that the columns can become overloaded, which affects the chromatography and it needs a modified inlet or injection port. Capillary columns are also generally more expensive.
4. When is it appropriate to use temperature programming? What are the advantages of using temperature programming? If there is a wide range of boiling points, the analyst needs to increase the column temperature over time in order to elute the high boiling point compounds of interest. Besides decreasing the time needed for analysis, temperature programming provides improved peak shapes, and because later peaks are now taller and sharper, it provides better detection.

5. GC commonly uses four different gases. Air, Nitrogen, Helium and Hydrogen. What is the purpose of each gas, how is it used and at what flow rates?
   
   • Air is typically used as the oxidant to support the flame in a FID detector. Typical flows are 350 – 450 mls/min.
   
   • Nitrogen and Helium are typically used as carrier gases. The type of carrier gas used is dependent on the detector used. For capillary and megabore columns, typical flows are 0.5 – 10mls/min, for packed columns 8 – 40 mls/min. Nitrogen and helium can also be used as make-up gas in an FID detector when using capillary columns. Make-up gas + column flow in a FID detector typically should be 25- 30mls/min.
   
   • Hydrogen is typically used as the fuel to support the flame in a FID detector. Typical flow rates are 30 ml/min. It is also sometimes used as a carrier gas due of its high efficiency in temperature programming as per the van Deemter curve.

6. (To be done at completion of each chromatography section.) Prepare a chart, comparing and relating each of techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling and sampling techniques, automation, accuracy, and quantitation. See Attachment E

7.2.3(IV) High Performance Liquid Chromatography (HPLC)

1. Describe a typical ‘basic’ HPLC system and the purpose of each component.

   A typical liquid chromatograph consists of:

   • Reservoir - to contain the mobile phase.
   • Solvent Delivery or Pumping System – causes the mobile phase to flow through the system at a specified flow rate. Single or multi-pump designs are can be purchased.
   • Injector - to introduce the sample into the mobile phase. Autosamplers are commonly used.

For the most current and official copy, check QMiS.
Drug Chemistry Analysis

- Column - component in which the separation is achieved by different mechanisms such as partition, adsorption, or ion-exchange of compounds in the test solution between the mobile and stationary phases.
- Detector – detects or measures compounds as they elute from a column. Common detectors include Single Wavelength UV, Diode Array/UV, Refractive Index and Fluorescence.
- Data collection device - to receive and store detector output – usually a computer or integrator.

2. What is the difference between normal phase and reverse phase? List at least three column types for each phase.
   - Normal phase: polar stationary phases and nonpolar mobile phase
   - Reverse phase: non-polar stationary phase and polar mobile phase.
   - Examples of column type for each phase:
     - Reverse Phase: C18, C12, C8, C4, C2, C1, Phenyl
     - Normal Phase: Silica, CN, NH₂, PAC, Diol, Alumina

3. For the chromatograms obtained in exercise 2 ‘Acetaminophen and Caffeine Tablet’ calculate the following for each of the peaks: Retention Time, Retention Volume, Relative Retention Time to IS, Capacity Factor, Resolution, Tailing, Theoretical Plates, Height Equivalent Theoretical Plate, Peak Widths at base, half height, and 5% height. Also calculate one set of sample results using both peak area and peak height calculations. Are the results different? If so explain why differences may result.
   (Formulas and calculations to be shown) Example given below: (Student is to perform exercise using information obtained from experiment.)

For the most current and official copy, check QMiS.
**HPLC Exercise**

Note: Electronic integrators perform most of the following calculations in automated systems. However, it is important to verify if the formula used by the system conforms to the USP.

In which $V_a$ and $V_1$ are the retention volumes for the non-retained component and the compound under test, respectively. And $t_1$ and $t_2$ are the retention times measured from time of injection to time of elution of peak maximum.

**Capacity Factor Calculation ($k'$)**

$$k' = \frac{t_1}{t_a} - 1 = \frac{3.0 \text{ min}}{0.8 \text{ min}} - 1 = 3.8$$  \(\text{USP <621>}\)

---

For the most current and official copy, check QMiS.
Express $k'$ in terms of the amount of mobile phase it takes to elute each compound off the column using the retention volumes.

\[
k' = \frac{V_1 - V_a}{V_a} = \frac{3.35\text{cm} - 0.70\text{cm}}{0.70\text{cm}} = 3.8
\]

**Relative Retention Time ($R_R$) of Peak 2 with respect to Peak 1**

\[
R_R = \frac{t_2}{t_1} = \frac{7.0\text{ min}}{3.0\text{ min}} = 2.3 \quad \text{USP <621>}
\]
Resolution between Peak 1 and Peak 2

\[ R = \frac{2(t_2 - t_1)}{W_2 + W_1} \]

(The retention times and the widths have the same units)

The retention times and the widths have the same units.

\[ R = \frac{2(6.30\, \text{cm} - 3.35\, \text{cm})}{0.7 + 0.7} = 4.2 \]

Note: The USP provides another formula to determine resolution and the number of theoretical plates that are convenient when electronic integrators are used. Refer to USP <621>
Tailing Factor (T) Calculation

\[ T = \frac{W_{25\%}}{2f} = \frac{12.0\text{cm}}{5.0\text{cm} \times 2} = 1.2 \]

![Diagram of Tailing Factor](image)

Figure 3: Asymmetrical chromatographic

Number of Theoretical Plates (N)

Values from Figure 2

\[ N = 16 \left( \frac{t}{W} \right)^2 = 16 \left( \frac{3.35\text{cm}}{0.7\text{cm}} \right)^2 = 366.4 \]

Note: The USP provides another formula to be used with the value of \( W_{h/2} \), the peak width at half-height. There is also in the USP another convenient formula to be used when electronic integrators are used.

Calculations using peak areas and peak heights

For the most current and official copy, check QMiS.
"Peak areas and peak heights are usually proportional to the quantity of compound eluting. These are commonly measured by electronic integrators but may be determined by more classical approaches. Peak areas are generally used but may be less accurate if peak interference occurs.” Ref. "USP <621>.

4. What is the purpose of the internal standard used in exercise 2? Calculate one set of sample results without using the internal standard. Are the results different? If so explain why differences may result.

A major source of error in quantitative comparison is irreproducibility in the amount of sample injected, notably when manual injections are made with a syringe, in the case of GC methods. In these cases, the effects of variability can be minimized by addition of an internal standard. Today’s automatic injectors greatly improve the reproducibility of sample injections and reduce the need for internal standards. Ref. USP <621>.
Following, a theoretical calculation example using an internal standard:

<table>
<thead>
<tr>
<th>Injection</th>
<th>Area of Analyte</th>
<th>Area Internal Standard</th>
<th>Response Ratio (Analyte/Internal STD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STD</td>
<td>38.14009</td>
<td>35.60928</td>
<td>1.07107</td>
</tr>
<tr>
<td>Inj1</td>
<td>37.02482</td>
<td>36.19063</td>
<td>1.02305</td>
</tr>
<tr>
<td>Inj2</td>
<td>29.65308</td>
<td>27.93705</td>
<td>1.06142</td>
</tr>
<tr>
<td>STD</td>
<td>38.72269</td>
<td>34.96597</td>
<td>1.10744</td>
</tr>
</tbody>
</table>

Average of STD Bracket: 1.07274

Concentration of the STD (C): 10.143 mg in 50 mL volumetric flask: 0.20286 mg/mL

Label Claim of the product: 5 mg

Dilution Factor: 100

Sample weight: 0.36135 mg

Average tablet weight (ATW): 0.09059 mg

To determine the quantity, in mg, of the portions of tablet taken:

\[ mg = 100C \left( \frac{R_u}{R_s} \right) \left( \frac{ATW}{Sample\ Weight} \right) \]

Where \( R_u \) and \( R_s \) are the ratios of the peak responses of the corresponding analyte and internal standard peaks obtained from the Assay preparation and the Standard preparation, respectively.
Example for injection 1

\[ \text{mg} = 100 \times 0.20286 \left( \frac{1.02305}{1.07274} \right) \left( \frac{0.09059}{0.36135} \right) = 4.85 \text{mg} \]

Percent of label claim: \( 4.85/5 = 97.0\% \)

Example for injection 2

\[ \text{mg} = 100 \times 0.20286 \left( \frac{1.06142}{1.07274} \right) \left( \frac{0.09059}{0.36135} \right) = 5.03 \text{mg} \]

Percent of label claim: \( 5.03/5 = 100.6\% \)
Without using the internal standard...

We used peak responses instead of the ratios:

\[
mg = 100 \times 0.20286 \left( \frac{37.02482}{38.43139} \right) \left( \frac{0.09059}{0.36135} \right) = 4.90 \text{mg}
\]

Percent of label claim: 4.90/5 = 98.0%

\[
mg = 100 \times 0.20286 \left( \frac{29.65308}{38.43139} \right) \left( \frac{0.09059}{0.36135} \right) = 3.92 \text{mg}
\]

Percent of label claim: 3.92/5 = 78.4%

THERE IS A DIFFERENCE!

Sample and standard solutions that do NOT contain an internal standard CANNOT compensate for variations in injection systems, injection volumes and sample/standard solutions.

5. **When and why would someone use gradient elution in HPLC? What is the effect of temperature on HPLC? Would temperature programming such as found in GC be effective for HPLC?** Ref. USP <621>.

- "The technique of continuously changing the solvent composition during the chromatographic run is called gradient elution or solvent programming. It is sometimes used to chromatograph complex mixtures of components differing greatly in their capacity factors. By increasing the mobile phase strength over time during the chromatographic separation the separation time between components is decreased."

- "Retention time in all LC separations generally decreases with increase in temperature. Another effect is the increase of the column efficiency. At elevated temperatures, viscosity of liquids decreases, and the diffusion coefficient increases. However, temperature effects in HPLC are not as significant as in gas chromatography. Volatile solvents cannot be allowed to rise to higher temperatures, and the high temperature may influence the stability of the attached bonded ligands on the adsorbent surface. The common temperature range for HPLC is from ambient temperature up to 60 or 70 degrees C."

- Temperature programming is not effective for HPLC.
6. (To be done at completion of each chromatography section.) Prepare a chart, comparing and relating each of techniques used in chromatography for the following: column materials, separation theory, phases, equipment needed, ease of use, accuracy, sampling and sampling techniques, automation, accuracy, and quantitation. See Attachment E
7.2.4(I) Dissolution

1. What are the parameters that need be checked and corrected before dissolution can be run? Describe what effect each would have on an analysis.

- Temperature is to be at 37° C +/- 0.5°C (unless otherwise specified).
  - Temperatures higher or lower can affect the rate the product goes into solution.
- Rotation speed of paddle or basket.
  - The faster the speed the faster the product is likely to go into solution.
- Paddle or basket height or positioning.
  - Both are specified in the USP as 25 +/- 2mm from bottom of paddle/basket to interior vessel bottom. The distance can have a great affect for paddles which relates to the distance from the product. The affect is minimal for the basket where the product is within the basket.
- Other Physical Parameters (level, wobble or runout, centering, vibration, verticality or perpendicularity).
  - If these parameters are not correct, they can alter the dissolution rates generally resulting in erroneous results.
- The vessel also needs to be checked physically for proper dimensions, cleanliness, irregularities and for micro-fractures or scratches in the glass.
  - Improper dimensions and irregularities can cause turbulence and interferences.
- Each method in the USP is developed using a specified set of parameters. The ‘Q’ value and general limits of each (extended release) product are established using the parameters listed. If any parameter is not correct, then the Dissolution analysis is not valid.

2. Exercise 2 demonstrates a profile analysis. When would this technique be used? For what type of products could this technique be used? Look in the USP and list a monograph that uses a profile type analysis. Use this technique to determine the full-time range in which a tablet or capsule dissolves. This is frequently used to develop dissolution methods and determine the optimal time that the ‘Q’ value is established. A modified form of the profile technique is used for controlled release products, where a sample solution is drawn at set times over an extended period. Frequently used for 6, 8, 12, 16 and 24 hr extended release capsules and tablets. Also, Transdermal Delivery Systems use modified procedures that determine a profile of a product over a period of time. The USP <724> describes several methods and acceptance tables for Extended-Release, Delayed Release and Transdermal Delivery Systems. Products include Clorpheniramine Maleate Extended Release Capsules, Aspirin Extended Release Tablets, and Nicotine Transdermal Systems.
3. Describe the reason and procedure for removing air from the dissolution media? Dissolved gases can cause bubbles to form, which may change the results of the test. Ref. USP <711>. One method of de-aeration is as follows: Heat the medium, while stirring gently to about 41°C. Immediately filter under vacuum using a filter having a porosity of 0.45 μm or less. Provide vigorous and continuous stirring of the filtrate under vacuum for 5 minutes. Media must be de-aerated immediately before use. Gently transfer the medium directly to the vessel. Do not introduce air into the medium. Other validated de-aeration techniques for removal of dissolved gases may be used. Ref. USP <711>. There are also commercial apparatus that use a vacuum to draw the medium through a fine pinhole into a large holding vessel.

4. Why not use water for all dissolution media and have constant paddle/basket rotation speed for all determinations? Many drugs are insoluble or have limited solubility in water. Buffers, dilute acids and surfactants are routinely used for Dissolution medium. They increase dissolution rates and stabilize the pH of resulting solutions. Test conditions such as pH and surface tension can vary depending on the source of water and may change during the dissolution test itself, due to the influence of the active and inactive ingredients. The paddle/basket speeds can affect the rate of dissolution, generally the faster the speed the faster the dissolution. Methods have been developed to optimize the paddle/basket speeds so that a satisfactory ‘Q’ value is obtained within a specified time.

5. Can one compare in-vitro dissolution results with in-vivo clinical studies? Explain the answer. Yes. In general, an in-vitro, in-vivo (IVIV) correlation has been recognized. It is the goal of the pharmaceutical scientist to find a relationship between an in-vitro characteristic of a dosage form and its in-vivo performance. An effort to connect dissolution and pharmacokinetics is often referred to as “in vitro-in vivo correlation” (IVIVC) analysis. Numerous IVIVC studies can be found in the literature. Controlled release products, rather than immediate release products, are the focused in the IVIVC literature. Since only products with dissolution rate-limited absorption (and with complete complete absorption) can be expected to exhibit a slope of one and zero intercept (Y=mX mX). The relationship is not as well defined for immediate release products, but depending on the in-vitro release rate and the in-vivo adsorption rate, the two methods are generally recognized as satisfactory for comparison.
<table>
<thead>
<tr>
<th>Title:</th>
<th>Drug Chemistry Analysis</th>
</tr>
</thead>
</table>

For the most current and official copy, check QMiS.
# Attachment E. Column Chromatography Chart

<table>
<thead>
<tr>
<th>Technique</th>
<th>TLC</th>
<th>Column</th>
<th>GC</th>
<th>HPLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Separation Technique</td>
<td>Adsorption, partition or a combination of both effects</td>
<td>Adsorption and Partition</td>
<td>Partition between gas phase and stationary phase</td>
<td>Partition, adsorption or ion-exchange</td>
</tr>
<tr>
<td>Phases</td>
<td><strong>Stationary</strong> Adsorbent – thin uniform layer or dry, finely powdered material such as silica gel or cellulose applied to a glass, plastic, or metal sheet or plate. <strong>Mobile</strong> Suitable solvent system</td>
<td><strong>Column Adsorption (CAC)</strong> Stationary Adsorbent – activated alumina or silica gel as a dry solid or as a slurry. <strong>Mobile</strong> Suitable solvent</td>
<td><strong>Stationary</strong> Solvent adsorbed on a solid support. <strong>Mobile</strong> Suitable solvent</td>
<td><strong>Stationary</strong> Solid or immobilized liquid stationary phase. Liquid phases are found in packed or capillary columns. <strong>Mobile</strong> Gaseous mobile phase</td>
</tr>
<tr>
<td>Equipment Needed</td>
<td>Glass plates, storage rack, adsorbent, spreader, developing chamber, template, micropipette, sprayer and ultraviolet light source.</td>
<td>Chromatographic tube, delivery tube to control the flow rates of solvent and a tamping rod</td>
<td>Carrier gas source, injection port or auto-injectors, column, heated oven compartment, detector, and data handling system</td>
<td>Mobile Solvent, Solvent Delivery System (Pump), Injector (Autoinjector), column, detector, and data handling system</td>
</tr>
<tr>
<td>Ease of Use</td>
<td>User Friendly</td>
<td>User Friendly</td>
<td>Moderate to complex depending on Instrumentation</td>
<td>Moderate to complex depending on detectors and data handling system</td>
</tr>
<tr>
<td>Accuracy</td>
<td>Used for semi-quantitative or quantitative estimation</td>
<td>Used for quantitative analysis with the aid of titrimetric or spectrophotometric determinative step</td>
<td>Reliable quantitative results are obtainable especially with internal standards and using auto-injectors or auto-samplers</td>
<td>Reliable quantitative results are obtainable especially with internal standards and auto-injectors or auto-samplers</td>
</tr>
<tr>
<td>Sampling Techniques</td>
<td>Apply the Test and Standard Solution as directed in the individual monograph and allow drying</td>
<td>CAC-Compounds are dissolved in a small amount of solvent and added to the top of the column. CPC-A solution of the sample in a small volume of the mobile phase is added to the top of the column. A solution of the sample in a small volume of the immobile phase is mixed with the solid support and transferred to the column</td>
<td>Compound of interest is to be volatile and thermally stable when heated. The test mixture either in a solution or as a gas may be injected directly into the column</td>
<td>Compounds are dissolved in a suitable solvent. This technique allows for thermally unstable and non-volatile compounds to be chromatographed.</td>
</tr>
<tr>
<td>Automation</td>
<td>Not normally Multi spotting equipment is available.</td>
<td>None</td>
<td>Auto-injectors, auto-samplers</td>
<td>Auto-injectors, auto-samplers</td>
</tr>
<tr>
<td>Cost</td>
<td>Moderately Inexpensive (&lt;$500)</td>
<td>Inexpensive (&lt;$100)</td>
<td>Expensive (&gt;15K +)</td>
<td>Expensive (&gt;20K +)</td>
</tr>
</tbody>
</table>